Halozyme Therapeutics (HALO) Expected to Post Quarterly Earnings on Thursday

Halozyme Therapeutics (NASDAQ:HALO) will likely be posting its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of $1.79 per share and revenue of $402.28 million for the quarter. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Investors may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.06. The company had revenue of $376.71 million for the quarter, compared to analysts’ expectations of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The business’s revenue was up 42.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.11 EPS. On average, analysts expect Halozyme Therapeutics to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $83.23 on Wednesday. Halozyme Therapeutics has a one year low of $59.38 and a one year high of $84.44. The company has a market cap of $9.87 billion, a PE ratio of 29.94, a P/E/G ratio of 0.34 and a beta of 0.85. The stock has a 50-day moving average of $75.09 and a 200-day moving average of $71.07. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33.

Insider Buying and Selling

In related news, Director Mahesh Krishnan sold 7,304 shares of the stock in a transaction on Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the sale, the director directly owned 14,462 shares of the company’s stock, valued at approximately $1,084,650. This represents a 33.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 1,923 shares of the firm’s stock in a transaction on Wednesday, July 8th. The shares were sold at an average price of $79.77, for a total value of $153,397.71. Following the transaction, the chief executive officer owned 767,780 shares in the company, valued at approximately $61,245,810.60. This trade represents a 0.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 72,477 shares of company stock worth $5,102,643. 2.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. WINTON GROUP Ltd purchased a new position in shares of Halozyme Therapeutics in the 3rd quarter worth approximately $257,000. Vontobel Holding Ltd. purchased a new stake in shares of Halozyme Therapeutics during the fourth quarter valued at approximately $255,000. Integrated Wealth Concepts LLC increased its position in shares of Halozyme Therapeutics by 6.8% during the fourth quarter. Integrated Wealth Concepts LLC now owns 3,563 shares of the biopharmaceutical company’s stock valued at $240,000 after acquiring an additional 228 shares during the last quarter. Abel Hall LLC bought a new stake in Halozyme Therapeutics during the third quarter worth $226,000. Finally, PCM Encore LLC bought a new stake in Halozyme Therapeutics during the fourth quarter worth $223,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

HALO has been the topic of several recent research reports. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Weiss Ratings upgraded Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday. Wall Street Zen raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. HC Wainwright reiterated a “buy” rating and issued a $95.00 target price on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Finally, Morgan Stanley reduced their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Eight analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $81.60.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.